MDA Stock Overview
MedApp S.A. develops mobile solutions for medicine in Poland.
Price History & Performance
|Historical stock prices|
|Current Share Price||zł0.54|
|52 Week High||zł1.51|
|52 Week Low||zł0.37|
|1 Month Change||-6.90%|
|3 Month Change||0%|
|1 Year Change||-44.22%|
|3 Year Change||-39.67%|
|5 Year Change||-50.00%|
|Change since IPO||500.00%|
Recent News & Updates
Why Investors Shouldn't Be Surprised By MedApp S.A.'s (WSE:MDA) 26% Share Price Surge
MedApp S.A. ( WSE:MDA ) shareholders are no doubt pleased to see that the share price has bounced 26% in the last...
|MDA||PL Healthcare Services||PL Market|
Return vs Industry: MDA underperformed the Polish Healthcare Services industry which returned -23.2% over the past year.
Return vs Market: MDA underperformed the Polish Market which returned -22.5% over the past year.
|MDA Average Weekly Movement||9.0%|
|Healthcare Services Industry Average Movement||7.3%|
|Market Average Movement||6.5%|
|10% most volatile stocks in PL Market||11.9%|
|10% least volatile stocks in PL Market||4.1%|
Stable Share Price: MDA is more volatile than 75% of Polish stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: MDA's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Polish stocks.
About the Company
MedApp S.A. develops mobile solutions for medicine in Poland. It offers CARNA LIFE, an analytical telemedicine system that enables patients to record their tests, as well as doctors to interpret the recorded tests. The CARNA LIFE product includes Carna Life Lite module, an application to record tests; and Carna Life Pro and Carna Life System modules that allow doctors to diagnose patients and monitor the state of their diabetes, high blood pressure, fever or hypothermia, atrial fibrillation, tachycardia, or cardiac arrhythmia.
MedApp Fundamentals Summary
|MDA fundamental statistics|
Is MDA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MDA income statement (TTM)|
|Cost of Revenue||zł3.20m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 12, 2022
|Earnings per share (EPS)||0.016|
|Net Profit Margin||29.24%|
How did MDA perform over the long term?See historical performance and comparison
Is MDA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MDA?
Other financial metrics that can be useful for relative valuation.
|What is MDA's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does MDA's PE Ratio compare to its peers?
|MDA PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
SNT Synektik Spólka Akcyjna
MRC Mercator Medical
Price-To-Earnings vs Peers: MDA is expensive based on its Price-To-Earnings Ratio (33.6x) compared to the peer average (9.1x).
Price to Earnings Ratio vs Industry
How does MDA's PE Ratio compare vs other companies in the European Healthcare Services Industry?
Price-To-Earnings vs Industry: MDA is expensive based on its Price-To-Earnings Ratio (33.6x) compared to the European Healthcare Services industry average (33.1x)
Price to Earnings Ratio vs Fair Ratio
What is MDA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||33.6x|
|Fair PE Ratio||33x|
Price-To-Earnings vs Fair Ratio: MDA is expensive based on its Price-To-Earnings Ratio (33.6x) compared to the estimated Fair Price-To-Earnings Ratio (33x).
Share Price vs Fair Value
What is the Fair Price of MDA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: MDA (PLN0.54) is trading below our estimate of fair value (PLN2.53)
Significantly Below Fair Value: MDA is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is MedApp forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score6/6
Future Growth Score 6/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MDA's forecast earnings growth (43.6% per year) is above the savings rate (2.6%).
Earnings vs Market: MDA's earnings (43.6% per year) are forecast to grow faster than the Polish market (7.6% per year).
High Growth Earnings: MDA's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: MDA's revenue (34.2% per year) is forecast to grow faster than the Polish market (5.5% per year).
High Growth Revenue: MDA's revenue (34.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MDA's Return on Equity is forecast to be high in 3 years time (29.5%)
Discover growth companies
How has MedApp performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MDA has a high level of non-cash earnings.
Growing Profit Margin: MDA's current net profit margins (29.2%) are lower than last year (32.1%).
Past Earnings Growth Analysis
Earnings Trend: MDA has become profitable over the past 5 years, growing earnings by 69.3% per year.
Accelerating Growth: MDA's earnings growth over the past year (57.3%) is below its 5-year average (69.3% per year).
Earnings vs Industry: MDA earnings growth over the past year (57.3%) exceeded the Healthcare Services industry -1.7%.
Return on Equity
High ROE: MDA's Return on Equity (16%) is considered low.
Discover strong past performing companies
How is MedApp's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: MDA's short term assets (PLN21.2M) exceed its short term liabilities (PLN6.4M).
Long Term Liabilities: MDA's short term assets (PLN21.2M) exceed its long term liabilities (PLN5.7K).
Debt to Equity History and Analysis
Debt Level: MDA is debt free.
Reducing Debt: MDA had no debt 5 years ago.
Debt Coverage: MDA has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: MDA has no debt, therefore coverage of interest payments is not a concern.
Discover healthy companies
What is MedApp current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MDA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MDA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MDA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MDA's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as MDA has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Mr. Krzysztof Medrala serves as Chairman of the Management Board at MedApp S.A. He serves as Member of Supervisory Board at Comperia.pl S.A. He was CEO of Origin - Investment Fund Company.Earlier he serve...
Experienced Board: MDA's board of directors are considered experienced (4.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
MedApp S.A.'s employee growth, exchange listings and data sources
- Name: MedApp S.A.
- Ticker: MDA
- Exchange: WSE
- Founded: 2010
- Industry: Health Care Technology
- Sector: Healthcare
- Implied Market Cap: zł135.072m
- Shares outstanding: 250.13m
- Website: https://medapp.pl
Number of Employees
- MedApp S.A.
- Armii Krajowej 25
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/10 00:00|
|End of Day Share Price||2022/08/10 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.